- Home
- Publications
- Publication Search
- Publication Details
Title
Novel therapies for hepatitis C — one pill fits all?
Authors
Keywords
-
Journal
NATURE REVIEWS DRUG DISCOVERY
Volume 12, Issue 8, Pages 595-610
Publisher
Springer Nature
Online
2013-06-28
DOI
10.1038/nrd4050
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Association Between Sustained Virological Response and All-Cause Mortality Among Patients With Chronic Hepatitis C and Advanced Hepatic Fibrosis
- (2013) Adriaan J. van der Meer et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- 65 SAFETY OF TRIPLE THERAPY WITH TELAPREVIR OR BOCEPREVIR IN HEPATITIS C PATIENTS WITH ADVANCED LIVER DISEASE – PREDICTIVE FACTORS FOR SEPSIS
- (2013) K. Rutter et al. JOURNAL OF HEPATOLOGY
- 5 PHASE 3 RANDOMIZED CONTROLLED TRIAL OF ALL-ORAL TREATMENT WITH SOFOSBUVIR + RIBAVIRIN FOR 12 WEEKS COMPARED TO 24 WEEKS OF PEG + RIBAVIRIN IN TREATMENT-NAÏVE GT2/3 HCV-INFECTED PATIENTS (FISSION)
- (2013) E. Gane et al. JOURNAL OF HEPATOLOGY
- 66 HIGH SUSTAINED VIRAL RESPONSE AT 12- AND 24-WEEK FOLLOW-UP OF MK-5172 WITH PEGYLATED INTERFERON alfa-2b AND RIBAVIRIN (PR) IN HCV GENOTYPE 1 TREATMENT-NAIVE NON-CIRRHOTIC PATIENTS
- (2013) M. Manns et al. JOURNAL OF HEPATOLOGY
- 798 EFFICACY OF TELAPREVIR DOSED TWICE DAILY VERSUS EVERY 8 HOURS BY IL28B GENOTYPE: RESULTS FROM THE PHASE III OPTIMIZE STUDY
- (2013) M. Buti et al. JOURNAL OF HEPATOLOGY
- 64 GS-5885 + GS-9451 + PEGINTERFERON AND RIBAVIRIN (PR) FOR SIX OR TWELVE WEEKS ACHIEVES HIGH SVR12 RATES IN TREATMENT-NAÏVE GENOTYPE 1 IL28B CC PATIENTS
- (2013) A. Thompson et al. JOURNAL OF HEPATOLOGY
- 881 HIGH SVR RATES (SVR4) FOR 12-WEEK TOTAL TELAPREVIR COMBINATION THERAPY IN IL28B CC TREATMENT-NAÏVES AND PRIOR RELAPSERS WITH G1 CHRONIC HEPATITIS C: CONCISE INTERIM ANALYSIS
- (2013) D.R. Nelson et al. JOURNAL OF HEPATOLOGY
- 60 SVR12 RATES AND SAFETY OF TRIPLE THERAPY INCLUDING TELAPREVIR OR BOCEPREVIR IN 221 CIRRHOTIC NON RESPONDERS TREATED IN THE FRENCH EARLY ACCESS PROGRAM (ANRS CO20-CUPIC)
- (2013) H. Fontaine et al. JOURNAL OF HEPATOLOGY
- 3 SAFETY AND EFFICACY OF INTERFERON-FREE REGIMENS OF ABT-450/r, ABT-267, ABT-333 +/− RIBAVIRIN IN PATIENTS WITH CHRONIC HCV GT1 INFECTION: RESULTS FROM THE AVIATOR STUDY
- (2013) K.V. Kowdley et al. JOURNAL OF HEPATOLOGY
- 1417 SUSTAINED VIROLOGIC RESPONSE WITH DACLATASVIR PLUS SOFOSBUVIR ± RIBAVIRIN (RBV) IN CHRONIC HCV GENOTYPE (GT) 1-INFECTED PATIENTS WHO PREVIOUSLY FAILED TELAPREVIR (TVR) OR BOCEPREVIR (BOC)
- (2013) M.S. Sulkowski et al. JOURNAL OF HEPATOLOGY
- 1413 SIMEPREVIR (TMC435) WITH PEGINTERFERON/RIBAVIRIN FOR TREATMENT OF CHRONIC HCV GENOTYPE-1 INFECTION IN TREATMENT-NAÏVE PATIENTS: RESULTS FROM QUEST-2, A PHASE III TRIAL
- (2013) M. Manns et al. JOURNAL OF HEPATOLOGY
- 1425 SIMEPREVIR (TMC435) WITH PEGINTERFERON/RIBAVIRIN FOR CHRONIC HCV GENOTYPE-1 INFECTION IN TREATMENT-NAÏVE PATIENTS: RESULTS FROM QUEST-1, A PHASE III TRIAL
- (2013) I. Jacobson et al. JOURNAL OF HEPATOLOGY
- 1430 SAFETY AND EFFICACY OF BOCEPREVIR/PEGINTERFERON/ RIBAVIRIN (BOC/P/R) COMBINATION THERAPY FOR CHRONIC HCV G1 PATIENTS WITH COMPENSATED CIRRHOSIS: A META-ANALYSIS OF FIVE PHASE 3 CLINICAL TRIALS
- (2013) J.M. Vierling et al. JOURNAL OF HEPATOLOGY
- A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus
- (2013) Ludmila Prokunina-Olsson et al. NATURE GENETICS
- Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options
- (2013) Ira M. Jacobson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Disease Eradication
- (2013) Donald R. Hopkins NEW ENGLAND JOURNAL OF MEDICINE
- Exploratory Study of Oral Combination Antiviral Therapy for Hepatitis C
- (2013) Fred Poordad et al. NEW ENGLAND JOURNAL OF MEDICINE
- Treatment of HCV Infection by Targeting MicroRNA
- (2013) Harry L.A. Janssen et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
- (2013) Eric Lawitz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life
- (2013) J. Guedj et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Resistance to mericitabine, a nucleoside analogue inhibitor of HCV RNA-dependent RNA polymerase
- (2012) Jean-Michel Pawlotsky et al. ANTIVIRAL THERAPY
- Evolving Epidemiology of Hepatitis C Virus in the United States
- (2012) R. Monina Klevens et al. CLINICAL INFECTIOUS DISEASES
- Viral Hepatitis in Liver Transplantation
- (2012) Gonzalo Crespo et al. GASTROENTEROLOGY
- New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives
- (2012) Christoph Welsch et al. GUT
- Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C
- (2012) Calogero Cammà et al. HEPATOLOGY
- Vitamin D binding protein gene polymorphisms and baseline vitamin D levels as predictors of antiviral response in chronic hepatitis C
- (2012) Edmondo Falleti et al. HEPATOLOGY
- Characterization of the inhibition of hepatitis C virus entry byIn vitro-generated and patient-derived oxidized low-density lipoprotein
- (2012) Sandra Westhaus et al. HEPATOLOGY
- Discovering the first microRNA-targeted drug
- (2012) Morten Lindow et al. JOURNAL OF CELL BIOLOGY
- 1206 ABT-072 OR ABT-333 COMBINED WITH PEGYLATED INTERFERON/RIBAVIRIN AFTER 3-DAY MONOTHERAPY IN HCV GENOTYPE 1 (GT1)-INFECTED TREATMENT-NAIVE SUBJECTS: 12-WEEK SUSTAINED VIROLOGIC RESPONSE (SVR12) AND SAFETY RESULTS
- (2012) F. Poordad et al. JOURNAL OF HEPATOLOGY
- 10 PEGINTERFERON LAMBDA-1A (LAMBDA) COMPARED TO PEGINTERFERON ALFA-2A (ALFA) IN TREATMENT-NAIVE PATIENTS WITH HCV GENOTYPES (G) 2 OR 3: FIRST SVR24 RESULTS FROM EMERGE PHASE IIB
- (2012) S. Zeuzem et al. JOURNAL OF HEPATOLOGY
- Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options
- (2012) Yoshiyuki Suzuki et al. JOURNAL OF HEPATOLOGY
- Suppression of Viral RNA Binding and the Assembly of Infectious Hepatitis C Virus Particles In Vitro by Cyclophilin Inhibitors
- (2012) A. Nag et al. JOURNAL OF VIROLOGY
- Preliminary Study of Two Antiviral Agents for Hepatitis C Genotype 1
- (2012) Anna S. Lok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Hepatitis C virus host cell entry
- (2012) Alexander Ploss et al. Current Opinion in Virology
- Three-Dimensional Architecture and Biogenesis of Membrane Structures Associated with Hepatitis C Virus Replication
- (2012) Inés Romero-Brey et al. PLoS Pathogens
- Second-wave Protease Inhibitors: Choosing an Heir
- (2011) Sandra Ciesek et al. Clinics in Liver Disease
- Toll-like receptors
- (2011) Eva Marie Y. Moresco et al. CURRENT BIOLOGY
- The green tea polyphenol, epigallocatechin-3-gallate, inhibits hepatitis C virus entry
- (2011) Sandra Ciesek et al. HEPATOLOGY
- Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in Humans: In Vitro and In Vivo Correlations
- (2011) Robert A. Fridell et al. HEPATOLOGY
- The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C
- (2011) Stefan Zeuzem et al. HEPATOLOGY
- Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders
- (2011) Kazuaki Chayama et al. HEPATOLOGY
- Prevalence of chronic hepatitis B among foreign-born persons living in the United States by country of origin
- (2011) Kris V. Kowdley et al. HEPATOLOGY
- Role of Hepatitis C virus genotype 3 in liver fibrosis progression - a systematic review and meta-analysis
- (2011) A. Probst et al. JOURNAL OF VIRAL HEPATITIS
- Treatment of patients with genotype 3 chronic hepatitis C- current and future therapies
- (2011) Shiv K. Sarin et al. LIVER INTERNATIONAL
- Boceprevir for Untreated Chronic HCV Genotype 1 Infection
- (2011) Fred Poordad et al. NEW ENGLAND JOURNAL OF MEDICINE
- Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection
- (2011) Bruce R. Bacon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Telaprevir for Retreatment of HCV Infection
- (2011) Stefan Zeuzem et al. NEW ENGLAND JOURNAL OF MEDICINE
- Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection
- (2011) Ira M. Jacobson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Hepatitis c virus and host cell lipids: An intimate connection
- (2011) Gualtiero Alvisi et al. RNA Biology
- New Insights into the HCV Quasispecies and Compartmentalization
- (2011) Patrizia Farci SEMINARS IN LIVER DISEASE
- ITPA Polymorphism Affects Ribavirin-Induced Anemia and Outcomes of Therapy—A Genome-Wide Study of Japanese HCV Virus Patients
- (2010) Hidenori Ochi et al. GASTROENTEROLOGY
- A Sustained Virologic Response Is Durable in Patients With Chronic Hepatitis C Treated With Peginterferon Alfa-2a and Ribavirin
- (2010) Mark G. Swain et al. GASTROENTEROLOGY
- Sustained virological response with 29 days of Debio 025 monotherapy in hepatitis C virus genotype 3
- (2010) H. Patel et al. GUT
- Patatin-Like phospholipase domain-containing 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C
- (2010) Luca Valenti et al. HEPATOLOGY
- Small molecule scavenger receptor BI antagonists are potent HCV entry inhibitors
- (2010) Andrew J. Syder et al. JOURNAL OF HEPATOLOGY
- Vitamin D deficiency and a CYP27B1-1260 promoter polymorphism are associated with chronic hepatitis C and poor response to interferon-alfa based therapy
- (2010) Christian Markus Lange et al. JOURNAL OF HEPATOLOGY
- Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect
- (2010) Min Gao et al. NATURE
- ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C
- (2010) Jacques Fellay et al. NATURE
- Prevalence, incidence, and residual risk of human immunodeficiency virus and hepatitis C virus infections among United States blood donors since the introduction of nucleic acid testing
- (2010) Shimian Zou et al. TRANSFUSION
- GT-1a or GT-1b Subtype-Specific Resistance Profiles for Hepatitis C Virus Inhibitors Telaprevir and HCV-796
- (2009) M. F. McCown et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Resistance to Direct Antiviral Agents in Patients With Hepatitis C Virus Infection
- (2009) Christoph Sarrazin et al. GASTROENTEROLOGY
- The cyclophilin inhibitor Debio 025 combined with PEG IFNα2a significantly reduces viral load in treatment-naïve hepatitis C patients
- (2009) Robert Flisiak et al. HEPATOLOGY
- Public health impact of antiviral therapy for hepatitis C in the United States
- (2009) Michael L. Volk et al. HEPATOLOGY
- Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients
- (2009) Simone Susser et al. HEPATOLOGY
- Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance
- (2009) Dongliang Ge et al. NATURE
- Interferon-alfa, interferon-λ and hepatitis C
- (2009) Thomas R O'Brien NATURE GENETICS
- IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy
- (2009) Vijayaprakash Suppiah et al. NATURE GENETICS
- Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C
- (2009) Yasuhito Tanaka et al. NATURE GENETICS
- Therapeutic Silencing of MicroRNA-122 in Primates with Chronic Hepatitis C Virus Infection
- (2009) R. E. Lanford et al. SCIENCE
- Eradication of Hepatitis C Virus in Patients Successfully Treated for Chronic Hepatitis C
- (2008) Sarah Maylin et al. GASTROENTEROLOGY
- Discovery of a hepatitis C target and its pharmacological inhibitors by microfluidic affinity analysis
- (2008) Shirit Einav et al. NATURE BIOTECHNOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started